Stephen F. Betz - Dec 15, 2022 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
Chief Scientific Officer
Signature
/s/ Marc Wilson, as attorney-in-fact
Stock symbol
CRNX
Transactions as of
Dec 15, 2022
Transactions value $
-$50,016
Form type
4
Date filed
12/19/2022, 04:11 PM
Previous filing
Dec 5, 2022
Next filing
Jan 5, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Sale -$50K -3.13K -3.65% $16.00 82.4K Dec 15, 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.
F2 Includes 561 shares acquired under the Issuer's Employee Stock Purchase Plan in November 2022 by the Reporting Person.